RSS Alerts

Latest News

  • Fresh hope for thousands of rheumatoid arthritis (RA) sufferers who cannot tolerate the most common treatment for this debilitating disease
    Data published today in The Lancet show that over 50% of RA patients can achieve low disease activity or remission with RoActemra, compared to under 20% of those treated with the most widely prescribed anti-TNF Humira when neither drug is combined with methotrexate (51.5% vs. 19.8%, assessed by DAS28 =3.2*). The study exposed a wealth of data indicating the superiority of RoActemra over Humira, with almost four times as many patients achieving disease remission with RoActemra alone, compared to Humira alone (39.9% vs. 10.5%, assessed by DAS28 <2.6*) and almost twice as many patients achieve a 70% improvement in the signs and symptoms of their disease (32.5% vs. 17.9%, assessed by ACR70**).
  • Marinomed´s Antiviral Nasal Spray Approved For Use In Canada
    An innovative nasal spray that has been proven clinically effective against respiratory viruses has now been authorized for the Canadian market. The product, which was developed by the Viennese biotech company Marinomed, reduces the reproduction and spread of viruses on the nasal mucosa and is based on Marinomed's proprietary technology platform Mavirex®. Based on the expected market success of the nasal spray, one major international pharmaceutical concern has already decided to market the product in the fall.
  • The world’s first (official) biosimilar antibody goes to… rheumatoid arthritis
    Remsima is only the first officially approved biosimilar antibody for RA therapy as Reditux, a MabThera biosimilar, was launched in India in 2007, but under unapproved biosimilar development guidelines.
  • ELRIG Bioprocess Conference
    The ELRIG meeting on High Throughput BioProcess development is only a few weeks away.
  • GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
    GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip
view more

Podcasts

  • Evotec strengthens and expands its Alliance Business
    Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Prior to assuming responsibility for Business Development in 2005, Dr Ashton held a number of positions within Operations at Evotec: He joined the Company in 1995 as one of the initial employees of the Discovery Division, becoming Department Manager in 2001, Director of Chemistry Services in 2002 and taking over responsibility for Evotec's Discovery Services Division in 2004, where he had responsibility for Evotec's screening, parallel synthesis and medicinal chemistry operations. During his time at Evotec, Dr Ashton has managed a wide range of pharmaceutical and biotechnology related projects, including medicinal chemistry projects, design and synthesis of screening libraries and technology transfer projects and has been involved in the progression of a number of drug candidates into the clinic in numerous therapeutic areas. Dr Ashton has authored and co-authored a number of peer reviewed papers, articles and book chapters in addition to being named on a number of pharmaceutical patents. He is trained as a medicinal chemist. Prior to joining Evotec, Dr Ashton also had spells at ICI Pharmaceuticals and Organon Laboratories. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology. Before joining Evotec in 2001, Mark spent 13 years at British Biotech Pharmaceuticals where he led a number of medicinal chemistry programmes and was latterly Director of Chemistry. At British Biotech, Mark contributed to the discovery and development of six compounds that have progressed into human clinical trials. Before his career at British Biotech, Mark carried out post-doctoral research at the University of Oxford and at York University, Toronto and obtained a D. Phil in Chemistry from the University of York.
  • The Ubiquitin Story
    In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
  • Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
    Download the Califf, Behrman and Kramer podcast as an mp3 file
  • Dr Brent Vose outlines AstraZeneca's oncology pipeline.
    Download the Dr. Brent Vose podcast as an mp3 file
view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

  • Launch excellence for diabetes medicines
    Sarah Rickwood and Carolyn Gauntlett from the European Thought Leadership Group IMS Health discuss the market for non-insulin diabetes treatments.
  • A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges
    This review describes the biological technology of using Lactococcus lactis containing the nisin-modifying enzymes for producing thioether-stabilized therapeutic peptides.
  • Building on bortezomib: second generation proteasome inhibitors as anti-cancer therapy
    Inhibition of the proteasome is an effective anti-cancer therapeutic approach, as demonstrated by the first-in-class agent bortezomib. Various new proteasome inhibitors are now in development, including peptide boronic acid analogs MLN9708 and CEP-18770, peptide epoxyketones carfilzomib and PR-047, and NPI-0052, a beta-lactone compound. In this review the authors review the second-generation proteasome inhibitors and assess the potential pharmacologic impact of their different chemical properties.
  • Synthetic therapeutic peptides: science and market
    This review reports on the unexpected and considerable number of peptides that are currently available as drugs and the chemical strategies that were used to bring them into the market. As demonstrated in this review, peptide-based drug discovery could be a serious option for addressing new therapeutic challenges.
  • HIV-derived peptide mimics
    Peptides capable of mimicking functionally important regions of HIV proteins are excellent tools to explore structure and function of HIV proteins. Recent advances in the design and generation of HIV mimetic peptides are summarized in this article.
view more

25 Hottest Articles

view more
Copyright © 2013
Elsevier Ltd. All rights reserved.
Sitemap | Terms & Conditions | Privacy | Cookies | Website Design Working with water